Coronado Biosciences To Present At Upcoming Investor Conferences

BURLINGTON, Mass., Aug. 30, 2012 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc. (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy agents for the treatment of autoimmune diseases and cancer, today announced that Dr. Bobby W. Sandage, Jr., Coronado's President and CEO, will present at two investor conferences in early September.

Dr. Sandage will present at the Stifel Nicolaus Healthcare Conference on Wednesday, September 5, 2012 at 8:35am (ET). The conference will be held September 5-6, 2012 at The Four Seasons in Boston, MA. A webcast of the audio portion of the presentation will be available at on the Events & Webcasts page.

Dr. Sandage will also present at the BioCentury NewsMakers Conference on Friday, September 7, 2012 at 1:30pm (ET). The conference will be held on September 7, 2012 at the Millennium Broadway Hotel in New York City. 

About Coronado Biosciences

Coronado Biosciences is engaged in the development of novel immunotherapy biologic agents.  The company's two principal pharmaceutical product candidates in clinical development are: TSO ( Trichuris suis ova or CNDO-201), a biologic for the treatment of autoimmune diseases, such as Crohn's disease, ulcerative colitis and multiple sclerosis; and CNDO-109, a biologic that activates natural killer (NK) cells, for the treatment of acute myeloid leukemia (AML) and solid tumors.  For more information, please visit .

The Coronado Biosciences, Inc. logo is available at

Forward-Looking Statements

This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to the company's product development programs and any other statements that are not historical facts. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated risks relating to the results of research and development activities, uncertainties relating to preclinical and clinical testing, financing and strategic agreements and relationships, the early stage of products under development, our need for substantial additional funds, government regulation, patent and intellectual property matters; our dependence on third party suppliers and competition, as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.
CONTACT: Lucy Lu, MD, Executive Vice President &         Chief Financial Officer         Coronado Biosciences, Inc.         781-238-6619;         or         Tricia Swanson, Associate         The Trout Group, LLC.         646-378-2953;

Coronado Biosciences logo